Comparable stake leader
FMR LLC
SEC ownership of Roivant Sciences Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001635088.
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
- Public ticker
- ROIV on Nasdaq
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
FMR LLC
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
FMR LLC
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001635088
- Issuer location
- London
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Roivant Sciences Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
50/50
Latest evidence
30 Jun 2026
13F
13D/G
3/4/5
Lead comparable stake: 10%
13D/G row: FMR LLC
Showing 1-8 of 50 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 10%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
10%
MORGAN STANLEY
6.9%
QVT Financial LP
4.3%
Vivek Ramaswamy
3.6%
VIKING GLOBAL INVESTORS LP
3.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13F
13D/G
Company
|
10%
from 13D/G
|
$2,160,080,715
77,981,253 shares
|
— | 31 Mar 2026 |
| MORGAN STANLEY |
13F
13D/G
Company
|
6.9%
from 13D/G
|
$1,435,644,662
51,828,325 shares
|
— | 31 Mar 2026 |
| QVT Financial LP |
13F
13D/G
3/4/5
Company · Director by Deputization
|
4.3%
from 13D/G
|
$696,966,265
25,161,237 shares
|
— | 31 Mar 2026 |
| Vivek Ramaswamy |
3/4/5
13D/G
10%+ Owner · Ramaswamy Vivek
|
3.6%
from 13D/G
|
$1,012,161,165
69,161,839 shares
mixed-class rows
|
-$128,337,673 | 11 Dec 2025 |
| VIKING GLOBAL INVESTORS LP |
13D/G
3/4/5
13F
10%+ Owner · Company
|
3.4%
|
$356,989,793
23,594,831 shares
|
-$161,027,803 | 30 Sep 2025 |
| SB INVESTMENT ADVISERS (UK) LTD |
13D/G
13F
SB Investment Advisers (UK) Limited · Company
|
2.3%
|
$357,488,273
16,413,603 shares
|
-$520,575,193 | 31 Dec 2025 |
| Matthew Gline |
3/4/5
CEO, Director
|
2.3%
|
$461,480,476
16,659,945 shares
|
-$46,123,053 | 30 Jun 2026 |
| BlackRock, Inc. |
13F
Company
|
6.2%
|
$1,225,842,982
44,254,260 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$895,409,292.
Buys
$49,957
Insiders: 1
Sells
$895,459,249
Insiders: 12
Net
-$895,409,292
Shares: -37,621,468
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 3,315
Shares: 37,624,783
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 6,432,013 | $0 | $217,269,556 | -$217,269,556 |
| 3-6 | 0 | 7,542,192 | $0 | $203,452,165 | -$203,452,165 |
| 6-9 | 0 | 19,173,003 | $0 | $411,603,392 | -$411,603,392 |
| 9-12 | 3,315 | 4,477,575 | $49,957 | $63,134,136 | -$63,084,179 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 25 reporting-owner rows connected to Roivant Sciences Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
25
Largest Forms 3/4/5 holder
Dexcel Pharma Technologies Ltd.
Net 12M change
-$895,409,290
Latest report
30 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Dexcel Pharma Technologies Ltd. | 10%+ Owner | $1,064,491,735 | Mixed | 10 Nov 2022 | ||
| Vivek Ramaswamy | 10%+ Owner | $1,012,161,165 | -$128,337,673 | -11% | Mixed | 11 Dec 2025 |
| SVF Investments (UK) Ltd | 10%+ Owner | $755,877,753 | Mixed | 28 Sep 2023 | ||
| Sumitomo Chemical Co., Ltd. | 10%+ Owner | $737,448,709 | Mixed | 22 Jun 2023 | ||
| Keith S. Manchester | Director | $544,934,662 | -$154,472,307 | -22% | Filing P/S | 26 Jun 2026 |
| Mayukh Sukhatme | President & CIO, Director | $516,071,470 | -$72,612,032 | -12% | Mixed | 30 Jun 2026 |
| QVT Financial LP | Director by Deputization | $482,953,776 | -$147,382,307 | -23% | Filing P/S | 26 Jun 2026 |
| Daniel Allen Gold | Director | $482,953,776 | -$147,382,307 | -23% | Filing P/S | 26 Jun 2026 |
| Matthew Gline | CEO, Director | $461,480,476 | -$46,123,053 | -9.1% | Mixed | 30 Jun 2026 |
| Frank Torti | President and Vant Chair | $374,952,795 | -$82,039,460 | -18% | Mixed | 30 Jun 2026 |
| Eric Venker | President & Immunovant CEO | $176,921,036 | -$103,472,446 | -37% | Mixed | 24 Jun 2026 |
| VIKING GLOBAL PERFORMANCE LLC | 10%+ Owner | $133,352,577 | Mixed | 22 Jun 2023 | ||
| VIKING GLOBAL INVESTORS LP | 10%+ Owner | $133,352,577 | Mixed | 22 Jun 2023 | ||
| Benjamin Zimmer | President, Roivant Health | $12,083,532 | Mixed | 01 Oct 2021 | ||
| Richard Pulik | Cfo | $7,656,834 | -$9,122,307 | -54% | Mixed | 20 Jun 2026 |
| Ilan Oren | Director | $3,330,343 | Mixed | 17 Apr 2026 | ||
| Jennifer Humes | Chief Accounting Officer | $3,040,961 | -$384,073 | -11% | Mixed | 20 Jun 2026 |
| James C. Momtazee | Director | $3,030,518 | Mixed | 17 Apr 2026 | ||
| Rakhi Kumar | Chief Accounting Officer | $1,739,920 | Mixed | 20 Feb 2025 | ||
| Meghan FitzGerald | Director | $1,499,408 | -$2,270,500 | -60% | Filing P/S | 30 Jun 2026 |
Recent insider transactions for Roivant Sciences Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Matthew Gline | ROIV | Common Shares | Tax liability | -0.46% | -76,171 | 16,659,945 | 30 Jun 2026 | Direct | ||
| Meghan FitzGerald | ROIV | Common Shares | Sale | -18.9% | $349,000 | $34.90 | -10,000 | 42,963 | 30 Jun 2026 | Direct |
| Meghan FitzGerald | ROIV | Common Shares | Options Exercise | 23.3% | 10,000 | 52,963 | 30 Jun 2026 | Direct | ||
| Meghan FitzGerald | ROIV | Stock Option (Right to Buy) | Options Exercise | -20.6% | -10,000 | 38,578 | 30 Jun 2026 | Direct | ||
| Frank Torti | ROIV | Common Shares | Tax liability | -0.3% | -40,310 | 13,536,202 | 30 Jun 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Tax liability | -0.25% | -46,878 | 18,630,739 | 30 Jun 2026 | Direct | ||
| Keith S. Manchester | ROIV | Common Shares | Sale | -10.3% | $7,090,000 | $35.45 | -200,000 | 1,748,403 | 30 Jun 2026 | Direct |
| Keith S. Manchester | ROIV | Common Shares | Sale | -0.09% | $436,766 | $35.28 | -12,380 | 13,689,166 | 30 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Daniel Allen Gold | ROIV | Common Shares | Sale | -0.09% | $436,766 | $35.28 | -12,380 | 13,689,166 | 30 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| QVT Financial LP | ROIV | Common Shares | Sale | -0.09% | $436,766 | $35.28 | -12,380 | 13,689,166 | 30 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Melissa B. Epperly | ROIV | Common Shares | Sale | -51.9% | $610,252 | $34.38 | -17,750 | 16,474 | 29 Jun 2026 | Direct |
| Melissa B. Epperly | ROIV | Common Shares | Options Exercise | 107.8% | 17,750 | 34,224 | 29 Jun 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Stock Option (Right to Buy) | Options Exercise | -9.5% | -17,750 | 169,166 | 29 Jun 2026 | Direct | ||
| Keith S. Manchester | ROIV | Common Shares | Sale | -5.52% | $27,642,000 | $34.55 | -800,000 | 13,701,546 | 29 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Daniel Allen Gold | ROIV | Common Shares | Sale | -5.52% | $27,642,000 | $34.55 | -800,000 | 13,701,546 | 29 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| QVT Financial LP | ROIV | Common Shares | Sale | -5.52% | $27,642,000 | $34.55 | -800,000 | 13,701,546 | 29 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Keith S. Manchester | ROIV | Common Shares | Sale | -4.14% | $21,275,309 | $34.00 | -625,783 | 14,501,546 | 26 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Daniel Allen Gold | ROIV | Common Shares | Sale | -4.14% | $21,275,309 | $34.00 | -625,783 | 14,501,546 | 26 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| QVT Financial LP | ROIV | Common Shares | Sale | -4.14% | $21,275,309 | $34.00 | -625,783 | 14,501,546 | 26 Jun 2026 | Held by QVT Financial Investment Cayman Ltd. |
| Mayukh Sukhatme | ROIV | Common Shares | Sale | -2.61% | $17,040,000 | $34.08 | -500,000 | 18,677,617 | 26 Jun 2026 | Direct |
| Mayukh Sukhatme | ROIV | Common Shares | Options Exercise | 2.68% | 500,000 | 19,177,617 | 26 Jun 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Stock Option (Right to Buy) | Options Exercise | -3.4% | -500,000 | 14,224,363 | 26 Jun 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Common Shares | Sale | -2.61% | $17,065,000 | $34.13 | -500,000 | 18,677,617 | 25 Jun 2026 | Direct |
| Mayukh Sukhatme | ROIV | Common Shares | Options Exercise | 2.68% | 500,000 | 19,177,617 | 25 Jun 2026 | Direct | ||
| Mayukh Sukhatme | ROIV | Stock Option (Right to Buy) | Options Exercise | -3.28% | -500,000 | 14,724,363 | 25 Jun 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -11% | $6,631,268 | $33.16 | -200,000 | 1,613,063 | 24 Jun 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Options Exercise | 12.4% | 200,000 | 1,813,063 | 24 Jun 2026 | Direct | ||
| Eric Venker | ROIV | Stock Option (Right to Buy) | Options Exercise | -4.5% | -200,000 | 4,244,834 | 24 Jun 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Tax liability | -0.76% | -2,129 | 276,420 | 20 Jun 2026 | Direct | ||
| Jennifer Humes | ROIV | Common Shares | Tax liability | -3.16% | -3,582 | 109,782 | 20 Jun 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -11% | $6,054,000 | $30.27 | -200,000 | 1,613,063 | 22 May 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Options Exercise | 12.4% | 200,000 | 1,813,063 | 22 May 2026 | Direct | ||
| Eric Venker | ROIV | Stock Option (Right to Buy) | Options Exercise | -4.31% | -200,000 | 4,444,834 | 22 May 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Tax liability | -2.09% | -34,483 | 1,613,063 | 20 May 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Tax liability | -6.37% | -18,962 | 278,549 | 20 May 2026 | Direct | ||
| Eric Venker | ROIV | Common Shares | Sale | -10.8% | $5,918,000 | $29.59 | -200,000 | 1,647,546 | 20 Apr 2026 | Direct |
| Eric Venker | ROIV | Common Shares | Options Exercise | 12.1% | 200,000 | 1,847,546 | 20 Apr 2026 | Direct | ||
| Eric Venker | ROIV | Stock Option (Right to Buy) | Options Exercise | -4.13% | -200,000 | 4,644,834 | 20 Apr 2026 | Direct | ||
| Richard Pulik | ROIV | Common Shares | Award | 25.6% | 60,644 | 297,511 | 20 Apr 2026 | Direct | ||
| Richard Pulik | ROIV | Stock Option (Right to Buy) | Award | 84,026 | 84,026 | 20 Apr 2026 | Direct | |||
| Jennifer Humes | ROIV | Common Shares | Award | 34.6% | 29,173 | 113,364 | 20 Apr 2026 | Direct | ||
| Jennifer Humes | ROIV | Stock Option (Right to Buy) | Award | 27,157 | 27,157 | 20 Apr 2026 | Direct | |||
| Ilan Oren | ROIV | Common Shares | Tax liability | -0.08% | -95 | 120,229 | 17 Apr 2026 | Direct | ||
| Ilan Oren | ROIV | Common Shares | Award | 0.75% | 896 | 120,324 | 17 Apr 2026 | Direct | ||
| Melissa B. Epperly | ROIV | Common Shares | Award | 4.24% | 670 | 16,474 | 17 Apr 2026 | Direct | ||
| James C. Momtazee | ROIV | Common Shares | Tax liability | -0.09% | -94 | 109,405 | 17 Apr 2026 | Direct | ||
| James C. Momtazee | ROIV | Common Shares | Award | 0.43% | 469 | 109,499 | 17 Apr 2026 | Direct | ||
| Matthew Gline | ROIV | Common Shares | Sale | -1.7% | $8,449,810 | $29.16 | -289,774 | 16,736,116 | 16 Apr 2026 | Direct |
| Jennifer Humes | ROIV | Common Shares | Sale | -13.8% | $384,073 | $28.37 | -13,538 | 84,191 | 08 Apr 2026 | Direct |
| Frank Torti | ROIV | Common Shares | Tax liability | -1.17% | -160,035 | 13,576,512 | 31 Mar 2026 | Direct |
* marks a reported price that did not pass the local price check.